Damora Therapeutics (DMRA) Shares Outstanding (Weighted Average) (2019 - 2026)

Damora Therapeutics (DMRA) has 8 years of Shares Outstanding (Weighted Average) data on file, last reported at $34.3 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 2494.47% year-over-year to $34.3 million; the trailing twelve-month figure through Mar 2026 stood at $34.3 million (up 2494.47% YoY), and the FY2025 full-year result was $1.4 million, up 17.79% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $34.3 million, up from $1.4 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $34.3 million in Q1 2026 and bottomed at $1.1 million in Q4 2023.
• The 5-year median for Shares Outstanding (Weighted Average) is $1.3 million (2025), against an average of $11.7 million.
• The widest annual swing landed in 2024, when Shares Outstanding (Weighted Average) plunged 95.89%; it then surged 2494.47% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $25.4 million in 2022, then plunged by 95.82% to $1.1 million in 2023, then climbed by 8.87% to $1.2 million in 2024, then gained by 17.79% to $1.4 million in 2025, then jumped by 2416.44% to $34.3 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $34.3 million (Q1 2026), $1.4 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.

Peer Comparison